Protocol I1F-MC-RHCD Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis Save

Date Added
June 27th, 2017
PRO Number
Pro00064844
Researcher
Lara Wine lee
Keywords
Drug Studies, Pediatrics, Skin
Summary

This is a clinical research trial that will evaluate whether an investigational drug called ixekizumab (given by injection) is safe and effective in children and young adults with moderate to severe plaque psoriasis. For more information, please call Abby Powell at (843) 792-6690.

Institution
MUSC
Recruitment Contact
Abby Powell
843-792-6690
powab@musc.edu

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma Save

Date Added
March 14th, 2017
PRO Number
Pro00063052
Researcher
Dirk Elston
Keywords
Cancer/Lymphoma, Skin
Summary

The purpose of this study is to test the safety and efficacy (how well the study medication works) of the experimental SGX301 drug in participants with cutaneous T-cell lymphoma in combination with light therapy using standard fluorescent lights.

Institution
MUSC
Recruitment Contact
Adrian Modzik
843-792-8385
modzik@musc.edu

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis. Save

Date Added
April 26th, 2016
PRO Number
Pro00054009
Researcher
Katherine Ruzhansky
Keywords
Drug Studies, Inflammation, Muscle, Rare Diseases, Skin
Summary

Subjects are being asked to volunteer for this research study because they have been diagnosed with Dermatomyositis (DM). This study will test the safety and effectiveness of the investigational new drug, IMO-8400. Subjects will receive a subcutaneous injection of the study drug or placebo once a week for up to 24 weeks during the study. Subjects will complete a total of 27 visits over the course of 32 weeks. After the baseline visit, subjects will have the option of having a visiting nurse (who has been trained in the protocol and approved by the Sponsor) conduct the intervening weekly study visits 2-25 outside of the clinic (e.g., at your home or workplace) rather than coming in to clinic for injections.

Institution
MUSC
Recruitment Contact
Christine Hudson
843-792-3790
hudsoncm@musc.edu

A phase 2 study to evaluate subcutaneous abatacept vs placebo in diffuse cutaneous systemic sclerosis-a double-blind, placebo-controlled, randomized controlled trial Save

Date Added
September 8th, 2015
PRO Number
Pro00043904
Researcher
Faye Hant
Keywords
Scleroderma, Skin
Summary

This study, comprised of an initial 12 month double-blind treatment phase of abatacept 125mg injected once a week vs placebo, followed by six month open label treatment phase, is designed to evaluate safety and effectiveness of the study drug, in subjects with diffuse systemic sclerosis.

Institution
MUSC
Recruitment Contact
Kelley Kajdasz
843-792-5290
gibsonke@musc.edu

Monitoring and Managing Newly Healed Chronic Leg and Foot Ulcer Skin Temperature: A Cooling Intervention (MUSTCOOL) to Prevent Ulcer Recurrence Save

Date Added
June 2nd, 2015
PRO Number
Pro00043450
Researcher
Teresa Kelechi
Keywords
Aging, Circulation, Diabetes, Inflammation, Skin, Vascular
Summary

Individuals with venous leg and diabetic foot ulcers often find these ulcers take a long time to heal and when they do, sometimes they come back. These ulcers can be quite painful making it hard to work, sleep and go about one's day to day activities. You will be asked to do a self-care routine of taking the temperature of the skin where the leg or foot ulcer just healed with a special thermometer and applying a small cooling gel patch over this skin. We want to know if this routine will prevent the ulcer from coming back, help you to become more active, and improve the quality of your life.

Institution
MUSC
Recruitment Contact
Margaret Prentice
843 792 4771
prenticm@musc.edu

Safety and Suitability of Dabigatran to Inhibit Thrombin in Scleroderma Save

Date Added
May 19th, 2015
PRO Number
Pro00042421
Researcher
Richard Silver
Keywords
Autoimmune disease, Lung, Scleroderma, Skin
Summary

This is a six month study to test the safety and suitability of dabigatran etexilate for the treatment of scleroderma-related interstitial lung disease.

Institution
MUSC
Recruitment Contact
Kelley Kajdasz
843-792-5290
gibsonke@musc.edu

FOOTFIT Mhealth Physical Activity Intervention for Leg Ulcer Patients Save

Date Added
May 5th, 2015
PRO Number
Pro00043451
Researcher
Teresa Kelechi
Keywords
Aging, Circulation, Exercise, Skin, Vascular
Summary

This study will test a low intensity foot exercise program for people with lower leg ulcers and who have problems with walking to see if it improves the condition of the legs. A small activity monitoring tracker called an accelerometer will be placed on the foot during the exercises that are to be done in the home for about 6 weeks. The tracker sends movement information to a cell phone that lets you and your doctor know about improvements in the foot movements. Better foot movements help condition the muscles and joints and may improve activity such as walking and getting up from a chair.

Institution
MUSC
Recruitment Contact
Darla Howard
864-560-1042
dhoward@srhs.com

The role of Innate Immunity in the Development of Phenotypic Keloid Disease Save

Date Added
June 29th, 2013
PRO Number
Pro00019607
Researcher
Titus Reaves
Keywords
Immune System, Skin, Vitamin D
Summary

Keloid disease predominantly affects African Americans, Hispanics and some Asians. Keloid disease is characterized by an overgrowth of an area of the skin following some injury to that same skin area. It is unknown why this occurs. However, we believe that differences in Vitamin D along with dysfunction in certain immune system receptors can lead to keloid disease. To further understand this process we intend to study the cells (fibroblasts) in the skin that are affected by Vitamin D and examine the specific immune proteins.

Institution
MUSC
Recruitment Contact
Jacqueline Savage
(843) 792-9372; (843) 792-1870
savageja@musc.edu, reaves@musc.edu

Change_preferences

-- OR --

Create_login